Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.
about
Glucose Augments Killing Efficiency of Daptomycin Challenged Staphylococcus aureus Persisters2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitisAdjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.A current perspective on daptomycin for the clinical microbiologist.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.Bacterial meningitis: current therapy and possible future treatment options.Treatment of bacterial meningitis: an update.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Bacterial meningitis: new therapeutic approaches.Bacterial meningitis: insights into pathogenesis and evaluation of new treatment options: a perspective from experimental studies.Bacterial meningitis: an update of new treatment options.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Central Nervous System Device Infections.Clinical Experience with Daptomycin in Pediatrics.Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm.Therapeutic Approaches for Zika Virus Infection of the Nervous System.Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
P2860
Q28550612-9E51A0C0-4435-4212-9BF8-5BCEDC09E9A7Q30274757-05746F40-817F-4F34-8ADC-19BA6AEA19C4Q35977518-83154A88-4C6F-4552-97DE-EC95D910E7D7Q36171566-4C0A990C-8844-4FA9-A6EC-47ADD583B43EQ37263289-49F5BA9B-2E74-4B16-990B-C979460B8261Q37287661-2A982094-A6C8-423F-9D8F-B33E63EF2DDFQ37949641-A4B900D9-8C83-4939-AAB9-C6FD0083EC37Q38044024-ACCFC6DF-383F-4E98-84DD-EAA357976484Q38100704-34522440-C2CD-41F8-AB95-6CA5F5AB4797Q38145360-EA14DACD-E36C-4F12-BE4F-81708082EE18Q38539643-0A7B08FC-11B8-4075-BA45-28B27EBADC93Q38570487-1EA913C7-3948-4DC5-B03E-B90C5CA2BB57Q38895642-06CD28F1-D95F-4EE8-BD37-75EC6827AB60Q38968171-D3E72318-388D-4D46-8CA1-C3A1DE650527Q39015261-782EE2DE-4C5E-42FF-9AEE-2C688EDB619EQ40047150-32EA8841-0185-47D5-BBBE-F6BC1DE8BF41Q41593734-EACACFB1-D89E-45D3-935F-E3D65A9B8C48Q41918254-BDAE26B2-9C24-4E75-94E9-8E47323EA814Q42217460-6A2D01C2-E5A8-44BC-ADDA-ABF250C78E77
P2860
Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetics of single-dos ...... irmed neurological infections.
@ast
Pharmacokinetics of single-dos ...... irmed neurological infections.
@en
type
label
Pharmacokinetics of single-dos ...... irmed neurological infections.
@ast
Pharmacokinetics of single-dos ...... irmed neurological infections.
@en
prefLabel
Pharmacokinetics of single-dos ...... irmed neurological infections.
@ast
Pharmacokinetics of single-dos ...... irmed neurological infections.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of single-dos ...... irmed neurological infections.
@en
P2093
David J Edwards
Dennis Parker
Judy N Chin
Michael J Rybak
Ravina Kullar
William M Coplin
P2860
P304
P356
10.1128/AAC.01741-10
P407
P577
2011-04-18T00:00:00Z